{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:04:00Z","timestamp":1768035840119,"version":"3.49.0"},"reference-count":17,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,2,7]],"date-time":"2016-02-07T00:00:00Z","timestamp":1454803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Otolaryngology"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this study was to investigate the impact of co\u2010existent chronic lymphocytic thyroiditis (<jats:styled-content style=\"fixed-case\">CLT<\/jats:styled-content>) on changes in serum antithyroglobulin antibody (TgAb) and clinical outcome in papillary thyroid carcinoma (<jats:styled-content style=\"fixed-case\">PTC<\/jats:styled-content>) patients with high preoperative serum TgAb.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>A retrospective cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>University teaching hospital.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Thirty\u2010seven <jats:styled-content style=\"fixed-case\">PTC<\/jats:styled-content> patients with high preoperative serum TgAb level (\u2265100 U\/mL) were evaluated. All patients underwent total thyroidectomy followed by high\u2010dose I\u2010131 ablation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Per cent changes of TgAb between pre\u2010treatment and post\u2010treatment, and disease\u2010free survival were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010two patients (59.5%) had co\u2010existent <jats:styled-content style=\"fixed-case\">CLT<\/jats:styled-content>, and seven had residual\/recurrent tumours. There was a higher proportion of females among the patients with <jats:styled-content style=\"fixed-case\">CLT<\/jats:styled-content> compared to those without <jats:styled-content style=\"fixed-case\">CLT<\/jats:styled-content> (95.5% <jats:italic>versus<\/jats:italic> 66.7%; <jats:italic>P<\/jats:italic> = 0.0306). There were trends towards more aggressive pathologies, such as tumour size, extrathyroidal extension, surgical margin and lymph node stage, in <jats:styled-content style=\"fixed-case\">PTC<\/jats:styled-content> without <jats:styled-content style=\"fixed-case\">CLT<\/jats:styled-content> than in that with co\u2010existent <jats:styled-content style=\"fixed-case\">CLT<\/jats:styled-content>. Pre\u2010treatment and post\u2010treatment TgAb were all higher in <jats:styled-content style=\"fixed-case\">PTC<\/jats:styled-content> with co\u2010existent <jats:styled-content style=\"fixed-case\">CLT<\/jats:styled-content>. But, per cent changes of TgAb between pre\u2010treatment and post\u2010treatment were no significant difference between <jats:styled-content style=\"fixed-case\">PTC<\/jats:styled-content> with and without <jats:styled-content style=\"fixed-case\">CLT<\/jats:styled-content> (<jats:italic>P<\/jats:italic> &lt; 0.05). Patients with co\u2010existent <jats:styled-content style=\"fixed-case\">CLT<\/jats:styled-content> showed a significantly lower residual\/recurrent tumour rate than those without <jats:styled-content style=\"fixed-case\">CLT<\/jats:styled-content> (4.5% <jats:italic>versus<\/jats:italic> 40%; <jats:italic>P<\/jats:italic> = 0.0113).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Residual\/recurrent tumour rate was lower in <jats:styled-content style=\"fixed-case\">PTC<\/jats:styled-content> patients with co\u2010existent <jats:styled-content style=\"fixed-case\">CLT<\/jats:styled-content> than in those without <jats:styled-content style=\"fixed-case\">CLT<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/coa.12520","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T04:31:05Z","timestamp":1439872265000},"page":"358-364","source":"Crossref","is-referenced-by-count":10,"title":["Impact of co\u2010existent thyroiditis on clinical outcome in papillary thyroid carcinoma with high preoperative serum antithyroglobulin antibody: a retrospective cohort study"],"prefix":"10.1111","volume":"41","author":[{"given":"H.\u2010Y.","family":"Nam","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine Samsung Changwon Hospital Sungkyunkwan University School of Medicine Changwon Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology Samsung Changwon Hospital Sungkyunkwan University School of Medicine Changwon Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.C.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Samsung Changwon Hospital Sungkyunkwan University School of Medicine Changwon Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,2,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.18.2164"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03537.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1998.8.197"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.2.5443"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.1998.00363.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2735"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0962"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00010"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2012.27.8.883"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5302.960"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-69-4-832"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.75.2.596"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0b013e328345f8be"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.1639"},{"key":"e_1_2_9_17_1","first-page":"1478","article-title":"Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study","volume":"33","author":"Rubello D.","year":"1992","journal-title":"J. Nucl. Med."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002680020165"}],"container-title":["Clinical Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcoa.12520","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/coa.12520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:54:32Z","timestamp":1695542072000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/coa.12520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,7]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/coa.12520"],"URL":"https:\/\/doi.org\/10.1111\/coa.12520","archive":["Portico"],"relation":{},"ISSN":["1749-4478","1749-4486"],"issn-type":[{"value":"1749-4478","type":"print"},{"value":"1749-4486","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,7]]}}}